CON: The black box warning on droperidol should not be removed (but should be clarified!)

Anesthesia and Analgesia

Volumn 106, Issue 5, 2008, Pages 1418-1420

  Ludwin, Danielle B ^a,b   Shafer, Steven L ^a  

^a Howard Hughes Medical Institute   (United States)

^b P and S Box 46 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DROPERIDOL; HALOPERIDOL; PROMETHAZINE; ANTIEMETIC AGENT;

DRUG APPROVAL; DRUG EFFICACY; DRUG LABELING; DRUG LEGISLATION; DRUG MARKETING; DRUG PACKAGING; DRUG SAFETY; EDITORIAL; ELECTROCARDIOGRAPHY MONITORING; FOOD AND DRUG ADMINISTRATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; LOW DRUG DOSE; NONHUMAN; POSTOPERATIVE NAUSEA AND VOMITING; PRIORITY JOURNAL; QT PROLONGATION; TORSADE DES POINTES; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG EFFECT; DRUG UTILIZATION; EVIDENCE BASED MEDICINE; HEART MUSCLE CONDUCTION SYSTEM; LONG QT SYNDROME; NOMENCLATURE; NOTE; PATHOPHYSIOLOGY; SAFETY; UNITED STATES;

ANTIEMETICS; CONSUMER PRODUCT SAFETY; DOSE-RESPONSE RELATIONSHIP, DRUG; DROPERIDOL; DRUG APPROVAL; DRUG LABELING; DRUG UTILIZATION; EVIDENCE-BASED MEDICINE; HEART CONDUCTION SYSTEM; HUMANS; LONG QT SYNDROME; POSTOPERATIVE NAUSEA AND VOMITING; TERMINOLOGY AS TOPIC; TORSADES DE POINTES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 42449130116     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ane.0b013e3181684e6a     Document Type: Article

References (22)

1. Nuttall GA, Eckerman KM, Jacob KA, Pawlaski EM, Wigersma SK, Shirk Marienau ME, Oliver WC, Narr BJ, Ackerman MJ. Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and torsade de pointes in the general surgical population? Anesthesiology 2007;107:531-6
2. Guy JM, André-Fouet X, Porte J, Bertrand M, Lamaud M, Verneyre H. [Torsades de pointes and prolongation of the duration of QT interval after injection of droperidol]. Ann Cardiol Angeiol (Paris) 1991;40:541-5
3. Lischke V, Behne M, Doelken P, Schledt U, Probst S, Vettermann J. Droperidol causes a dose-dependent prolongation of the QT interval. Anesth Analg 1994;79:983-6
4. Frye MA, Coudreaut MF, Hakeman SM, Shah BG, Strouse TB, Skotzko CE. Continuous droperidol infusion for management of agitated delirium in an intensive care unit. Psychosomatics 1995;36: 301-5
5. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SJ. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000;355:1048-52
6. Drolet B, Zhang S, Deschênes D, Rail J, Nadeau S, Zhou Z, January CT, Turgeon J. Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current. J Cardiovasc Electrophysiol 1999;10:1597-604
7. Lehmann KA, Van Peer A, Ikonomakis M, Gasparini R, Heykants J. Pharmacokinetics of droperidol in surgical patients under different conditions of anaesthesia. Br J Anaesth 1988;61:297-301
8. White PF, Song D, Abrao J, Klein KW, Navarette B. Effect of low-dose droperidol on the QT interval during and after general anesthesia: A placebo-controlled study. Anesthesiology 2005;102:1101-5
9. Committee for Proprietary Medicinal Products (CPMP). Points to Consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. The European Agency for the Evaluation of Medicinal Products. December, 1997
10. Charbit B, Funck-Brentano C. Droperidol-induced proarrhythmia: the beginning of an answer? Anesthesiology 2007;107:524-6
11. Habib AS, Gan TJ. Food and drug administration black box warning on the perioperative use of droperidol: a review of the cases. Anesth Analg 2003;96:1377-9
12. Gan TJ, White PF, Scuderi PE, Watcha MF, Kovac A. FDA "black box" warning regarding use of droperidol for postoperative nausea and vomiting: is it justified? Anesthesiology 2002;97:287
13. Shafer SL. Safety of patients reason for FDA black box warning on droperidol. Anesth Analg 2004;98:551-2
14. Dershwitz M. There should be a threshold dose for the FDA black-box warning on droperidol. Anesth Analg 2003;97:1542-3
15. Scuderi PE. You (still) can't disprove the existence of dragons. Anesthesiology 2005;102:1081-2
16. Habib AS. PRO: The FDA black box warning on droperidol is not justified. Anesth Analg 2008;106:1414-7
17. Chang NS, Sinoe AF, Schultheis LW. From the FDA: What's in a label? A guide for the anesthesia practitioner. Anesthesiology 2005;103:179-85
18. Jacoby JL, Fulton J, Cesta M, Heller M. After the black box warning: dramatic changes in ED use of droperidol. Am J Emerg Med 2005;23:196
19. Sheth HS, Verrico MM, Skledar SJ, Towers AL. Promethazine adverse events after implementation of a medication shortage interchange. Ann Pharmacother 2005;39:255-61
20. Rosow CE, Haspel KL, Smith SE, Grecu L, Bittner EA. Haloperidol vs. ondansetron for prophylaxis of postoperative nausea and vomiting. Anesth Analg 2008;106:1407-9
21. Grecu L, Bittner EA, Kher J, Smith SE, Rosow CE. Haloperidol plus ondansetron vs. ondansetron alone for prophylaxis of postoperative nausea and vomiting. Anesth Analg 2008;106:1410-3
22. Chu CC, Shieh JP, Tzeng JI, Chen JY, Lee Y, Ho ST, Wang JJ. Postoperative nausea and vomiting in patients undergoing laparoscopically assisted vaginal hysterectomy. Anesth Analg 2008;106:1402-6